Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
NCT ID: NCT03029208
Last Updated: 2021-10-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
312 participants
INTERVENTIONAL
2017-05-11
2020-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Daprodustat treated anemic subjects
Subjects will receive oral daprodustat once daily.
Daprodustat
Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
Iron therapy
Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Darbepoetin alfa treated anemic subjects
Subjects will receive darbepoetin alfa subcutaneously or intravenously.
Darbepoetin alfa
Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Iron therapy
Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daprodustat
Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
Darbepoetin alfa
Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Iron therapy
Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planning to start chronic dialysis within the next 6 weeks (from the date of the screening visit) OR have started and received dialysis (as specified below) for end-stage renal disease for a maximum of \<=90 days immediately prior to randomization and is not expected to stop dialysis during the duration of the trial: HD \>=2 times per week or PD \>=4 times per week including incremental schedule; subjects on continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) are eligible.
* Hemoglobin concentration as measured by HemoCue (range inclusive): 8 to 10.5 g/dL (5-6.5 millimoles per liter \[mmol/L\]) at screening and 8-11.0 g/dL (5 to 6.8 mmol/L) at randomization.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
Exclusion Criteria
* Ferritin: \<=100 nanograms per milliliter (ng/mL) (\<=100 micrograms per liter \[mcg/L\]) at screening or after IV iron supplementation.
* Transferrin saturation (TSAT): \<=20% at screening or after IV iron supplementation.
* Vitamin B12 (cobalamin): Below the lower limit of the reference range at screening or after vitamin B12 supplementation.
* Folate: \<2.0 ng/mL (\<4.5 nanomoles per liter \[nmol/L\]) at screening.
* Aplasias: History of bone marrow aplasia or pure red cell aplasia (PRCA).
* Other causes of anemia: Untreated pernicious anemia, thalassemia major, sickle cell disease, or myelodysplastic syndrome.
* Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or clinically significant GI bleeding \<=10 weeks prior to screening through to randomization (Day 1).
* Use of any Erythropoiesis-stimulating agent (ESA) treatment within 8 weeks prior to screening except for limited use as part of dialysis initiation. Note : Limited use is defined as no more than 6 weeks of short acting ESA (rhEPO or biosimilars; maximum of 20000 unit total) or long acting ESA (darbepoetin alfa \[maximum of 100 mcg total\] or methoxy polyethylene glycol-epoetin beta \[maximum of 125 mcg total\]) received before or after starting dialysis.
* Myocardial infarction or acute coronary syndrome: \<=10 weeks prior to screening through to randomization (Day 1).
* Stroke or transient ischemic attack: \<=10 weeks prior to screening through to randomization (Day 1).
* Chronic Class IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.
* Current uncontrolled hypertension as determined by the Investigator that would contraindicate the use of rhEPO.
* QT correction using Bazett's (QTcB) (Day 1): QTcB \>500 milliseconds (msec), or QTcB \>530 msec in subjects with bundle branch block. There is no QTc exclusion for subjects with a predominantly ventricular paced rhythm.
* Liver disease (any one of the following): 1. Alanine transaminase (ALT) \>2 times upper limit of normal (ULN) (screening only). 2. Bilirubin \>1.5 times ULN (screening only) (NOTE: Isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). 3. Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease (including asymptomatic gallstones, chronic hepatitis B or C, or Gilbert's syndrome) are acceptable if subject otherwise meets entry criteria.
* History of malignancy within the 2 years prior to screening through to randomization (Day 1), or currently receiving treatment for cancer, or complex kidney cyst (i.e. Bosniak Category II F, III or IV) \>3 centimeter (cm). The only exception is localized squamous cell or basal cell carcinoma of the skin that has been definitively treated \>=10 weeks prior to screening.
* History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product or to darbepoetin alfa.
* Use of strong Cytochrome P4502C8 (CYP2C8) inhibitors (example gemfibrozil) or strong CYP2C8 inducers (example rifampin/rifampicin).
* Use of other investigational agent or device prior to screening through to randomization (Day 1). At screening, this exclusion applies to use of the investigational agent within 30 days or within five half-lives (whichever is longer).
* Any prior treatment with daprodustat for treatment duration of \>30 days.
* Females only: Subject is pregnant \[as confirmed by a positive serum human chorionic gonadotropin (hCG) test for females of reproductive potential (FRP) only\], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the contraceptive options in the List of Highly Effective Methods for Avoiding Pregnancy.
* Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (example intolerance to rhEPO) or prevent understanding of the aims or investigational procedures or possible consequences of the study.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Cerritos, California, United States
GSK Investigational Site
Escondido, California, United States
GSK Investigational Site
Glendale, California, United States
GSK Investigational Site
La Palma, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Lynwood, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Whittier, California, United States
GSK Investigational Site
Middlebury, Connecticut, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Augusta, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Crystal Lake, Illinois, United States
GSK Investigational Site
Fort Wayne, Indiana, United States
GSK Investigational Site
Merrillville, Indiana, United States
GSK Investigational Site
Michigan City, Indiana, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Baton Rouge, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Brooklyn, New York, United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Mineola, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Lufkin, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Hampton, Virginia, United States
GSK Investigational Site
Ciudad Evita, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Morón, Buenos Aires, Argentina
GSK Investigational Site
Pergamino, Buenos Aires, Argentina
GSK Investigational Site
Pilar, Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Formosa, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
St Albans, Victoria, Australia
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Düsseldorf, North Rhine-Westphalia, Germany
GSK Investigational Site
Kaiserslautern, Rhineland-Palatinate, Germany
GSK Investigational Site
Wiesbaden, , Germany
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Chennai, , India
GSK Investigational Site
Delhi, , India
GSK Investigational Site
Gurgaon, , India
GSK Investigational Site
Kozhikode, , India
GSK Investigational Site
New Delhi, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Secunderabad, , India
GSK Investigational Site
Thiruvananthapuram, , India
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Pavia, Lombardy, Italy
GSK Investigational Site
Cagliari, Sardinia, Italy
GSK Investigational Site
George Town, , Malaysia
GSK Investigational Site
Ipoh, , Malaysia
GSK Investigational Site
Kuala Lumpur, , Malaysia
GSK Investigational Site
Torreón, Coahuila, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Zapopan, Jalisco, Mexico
GSK Investigational Site
Ciudad de México, State of Mexico, Mexico
GSK Investigational Site
Mérida, Yucatán, Mexico
GSK Investigational Site
Mérida, Yucatán, Mexico
GSK Investigational Site
Aguascalientes, , Mexico
GSK Investigational Site
Tlalnepantla, , Mexico
GSK Investigational Site
Gdansk, , Poland
GSK Investigational Site
Koło, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Ostrołęka, , Poland
GSK Investigational Site
Ostróda, , Poland
GSK Investigational Site
Szczecin, , Poland
GSK Investigational Site
Irkutsk, , Russia
GSK Investigational Site
Mytishchi, , Russia
GSK Investigational Site
Omsk, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Smolensk, , Russia
GSK Investigational Site
Volzhskiy, , Russia
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Anyang-Si, Gyeonggi-do, , South Korea
GSK Investigational Site
Bucheon-si, , South Korea
GSK Investigational Site
Incheon, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Suwon, , South Korea
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Puerto Real, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Birmingham, , United Kingdom
GSK Investigational Site
Doncaster, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Middlesbrough, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 Jun 1;182(6):592-602. doi: 10.1001/jamainternmed.2022.0605.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-000507-86
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
201410
Identifier Type: -
Identifier Source: org_study_id